EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
14 févr. 2019 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
13 févr. 2019 16h15 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
04 févr. 2019 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
28 janv. 2019 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
EyePoint Pharmaceuticals Provides 2019 Commercial Update
03 janv. 2019 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
- DEXYCUTM commercial launch now expected in 1Q19, earlier than prior guidance of 1H19 - - YUTIQTM commercial launch on track for 1Q19 - WATERTOWN, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) --...
EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
17 déc. 2018 16h23 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic...
EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
27 nov. 2018 16h05 HE
|
EyePoint Pharmaceuticals, Inc.
- Industry veteran who brings over 25 years of legal expertise in the medical device industry to newly created position - WATERTOWN, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- EyePoint...
EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
12 nov. 2018 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
06 nov. 2018 16h10 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative...
EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments
06 nov. 2018 06h00 HE
|
EyePoint Pharmaceuticals, Inc.
-YUTIQ™ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using...